Celltrion and Thermo Fisher are reportedly vying to acquire the biopharma solutions unit of Baxter International.According to Reuters, the sale could go up as high as $4 billion, which would help alleviate Baxter's debt burden. Baxter's debt is considerably high at $16.6 billion as of the end of Dec
Researchers at the Korea Research Institute of Bioscience and Biotechnology (KRIBB) developed a bacterial cancer therapeutic that increases drug permeability in cancerous tissues when combined with chemotherapeutic drugs.Chemotherapy stops the growth of cancer cells which can be administered orally,
CHA University Bundang Medical Center (CBMC) said on Monday that its researchers proved the safety and effectiveness of dopamine neural precursor cells derived from fetal mesenchymal stem cells transplanted into patients with Parkinson's disease "for the first time in the world."Parkinson's disease
Following the Moon Jae-in government, the Yoon Suk Yeol administration also emphasizes the need to promote the bio-industry. Still, there is a shortage of workers who jump into this field, experts pointed out Friday.That and other issues were discussed during the “5th K-Life & Bio Forum” held at the
Samsung Biologics held a board of directors meeting on Friday and announced that it will invest 1.9 trillion won ($1.45 billion) to build Plant 5, its fifth biopharmaceutical contract manufacturing organization (CMO) plant in Songdo, Incheon.Plant 5 will be the first plant in Bio Campus 2 and will b
Researchers from Ajou University School of Medicine published a study demonstrating that it is safe to use attention deficit hyperactivity disorder (ADHD) medication and antidepressants together in adolescents.The research team led by professor Shin Yun-mi of psychiatry investigated 330,000 ADHD pat
The Korea Advanced Institute of Science and Technology (KAIST) said on Tuesday that its researchers have developed a clathrin assembly that can specifically deliver drugs to cancer cells for a wide variety of biomedical applications.Cancer is often difficult to treat because drug delivery systems th
Many Korean biopharmaceutical companies will participate in the “2023 BIO-Europe Spring” in Basel, Switzerland, from March 20-22. Attention is focused on whether the massive participation will be able to melt frozen bio-related investment sentiment at home and abroad.Multinational companies, includi
The biopharmaceutical industry expressed its intention to welcome the National Assembly’s move to include “bio-health” in the national strategic industry eligible for tax benefits.In a statement on Thursday, KoreaBIO said it warmly welcomed the revision bill proposed by 11 lawmakers, including Rep.
Korean biosimilar products are rapidly expanding their market share against original drugs in the local pharmaceutical sector.Initially, biosimilars failed to make a splash in the domestic market, unlike in Europe and the U.S., because biosimilar makers could not secure price competitiveness against
Speculations grow that the merger between Celltrion Group's major affiliates —Celltrion, Celltrion Healthcare, and Celltrion Pharm— will accelerate with the recently planned comeback of Seo Jung-jin, the honorary chairman of Celltrion Group.Industry watchers based their speculations on the group’s r
A joint research team at KAIST and Samsung Medical Center have found a new target protein, CEACAM1, which can improve immune anticancer therapies through selective removal of T-cells found in tumors.The study identified a new target protein CEACAM1 that enables the selective removal of regulatory T
Seo Jung-jin, honorary chairman of Celltrion Group, will return to management after leaving the company two years ago to start anew as a startup entrepreneur.Celltrion Group's major affiliates – Celltrion Holdings, Celltrion, Celltrion Healthcare, and Celltrion Pharma – held separate board meetings
Samsung Biologics said in a public filing on Thursday that it signed a contract manufacturing organization (CMO) deal with Pfizer worth $183 million (241 billion won), which is equivalent to 15.37 percent of total sales in 2021.The contract period is from February 20, 2023, to December 31, 2029. How
KAIST researchers have developed and verified a deep learning algorithm, that can detect differences in gene expression patterns between tumor cells and normal cells based on logic circuits, to optimize chimeric antigen receptor (CAR) cell therapies.Identifying optimal target antigens that distingui
For Korea’s digital healthcare startups, especially artificial intelligence-based ones, to grow, the government must introduce a separate insurance coverage system for the sector, an industry executive said recently.A doctor-turned-investor said so on social media on Tuesday, causing quite a stir in
Lotte Biologics said it decided to introduce a stock option system for workers employed at the Korean headquarters.According to the biopharmaceutical unit of retail giant Lotte, it is the first time since the founding of the Lotte Group that an affiliate has provided stock options to all employees w
PSMC will change its name to HLB innoVation at a shareholder meeting next month to emerge as the HLB Group’s key unit in developing CAR-T (chimeric antigen receptor-T cell) treatments. In a public disclosure on Friday, PSMC said it would change its corporate title to HLB innovation by holding an ext
Celltrion has come forward to explain reasons for the delayed approval of its Humira biosimilar, Yuflyma (CT-P17), in the U.S., saying there were some problems, but they have been solved now.In a letter to shareholders published on its website Thursday, Celltrion said it has acquired a sales permit
The police said they arrested an employee of Samsung Biologics who tried to take out the company's classified data without permission.The Incheon Metropolitan Police Agency said Thursday that it is investigating the Samsung Biologics employee on charges of violating the Unfair Competition Prevention